5 assets in Intrahepatic Bile Duct Cancer

Therapeutic assets addressing Intrahepatic Bile Duct Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Dexasone Intrahepatic Bile Duct Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Floxuridine Intrahepatic Bile Duct Cancer	Erasmus Medical Center	P2	CCC (53)
pds01adc Intrahepatic Bile Duct Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Cis-Diamminedichloroplatinum Ii Intrahepatic Bile Duct Cancer	National Cancer Institute (NCI)	P1	CC (43)
Elimusertib Intrahepatic Bile Duct Cancer	National Cancer Institute (NCI)	P1	CC (43)